FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Nashington,	D.C.	20549

ΗP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	Estimated average burden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BRADSHER NEAL C				2. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [LCTX]								(Che	5. Relationship of Reporting Person(s) to Issu (Check all applicable) X Director X 10% Ox					
(Last) (First) (Middle) C/O BROADWOOD CAPITAL INC.					3. Date of Earliest Transaction (Month/Day/Year) 07/01/2020								Officer (below)	give title		Other (below)	specify	
724 FIFTH AVENUE, 9TH FLOOR				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) NEW YOL	RK NY	1	10019								1 1	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Sta	ite) (Zip)															
		Tab	ole I - Noi	n-Deriv	/ativ	e Se	curities	s Ac	quired, [isp	osed o	f, or Bene	eficially	Owned				
1. Title of Security (Instr. 3) 2. Trans Date (Month)			action Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr.		ties Acquired I Of (D) (Instr.	(A) or 3, 4 and 5)	Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct Indirect	7. Nature of Indirect Beneficial Ownership			
									Amount	(A) or Price					(Instr. 4)			
		-										or Benef ble securi		Owned			•	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\	d Date,	4. Transa Code (ction	5. Number of		6. Date Exercisable Expiration Date (Month/Day/Year)		able and	7. Title and A of Securities Underlying I Security (Ins 4)	Amount S Derivative	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficial Owned Following Reported Transact (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		expiration Date	Title	Amount or Number of Shares					
OPTION TO PURCHASE COMMON SHARES	\$0.8263	07/01/2020			A		40,000		(1)	0	7/01/2030	COMMON SHARES	40,000	\$0 ⁽²⁾	40,00	00	D	
OPTION TO PURCHASE COMMON SHARES	\$1.03								(3)	0	6/30/2029	COMMON SHARES	40,000		40,00	00	D	
OPTION TO PURCHASE COMMON SHARES	\$2.06								(3)	0	6/30/2023	COMMON SHARES	49,440		49,44	10	D	
OPTION TO PURCHASE COMMON SHARES	\$3.15								(3)	0	6/30/2022	COMMON SHARES	24,720		24,72	20	D	
OPTION TO PURCHASE COMMON SHARES	\$2.72								(3)	0	6/30/2021	COMMON SHARES	24,720		24,72	20	D	

Explanation of Responses:

- 1. These options will vest and become exercisable on July 1, 2021, provided, that Neal C. Bradsher remains a member of the issuer's board of directors on that date.
- $2. \ The \ options \ were \ granted \ to \ Neal \ C. \ Bradsher \ by \ the \ issuer \ on \ July \ 1, \ 2020 \ as \ director \ compensation.$
- 3. These options are currently exercisable.

/s/ Neal C. Bradsher

07/02/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.